Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | ABL1 | P00519 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | PKM | P14618 | 1/20 | 0.91 |
| ▸ | IDE | P14735 | 1/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.91 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.91 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.91 |
| ▸ | HLCS | P50747 | 6/20 | 0.67 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379530 | 1.00 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16900247 | 1.00 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13958687 | 1.00 | TDP1 (0.91) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8763 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL14489489 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL38817 | 0.95 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2020-03-19 | — | — | US | disclosed |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090260682-A1 | QUANTUM DOT SOLAR CELL | HONEYWELL INTERNATIONAL INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090260682-A1 | QUANTUM DOT SOLAR CELL | HONEYWELL INTERNATIONAL INC. (US) | 2009-10-22 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070071673-A1 | Trifunctional reagent for conjugation to a biomolecule | MITRA MEDICAL TECHNOLOGY AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070071673-A1 | Trifunctional reagent for conjugation to a biomolecule | MITRA MEDICAL TECHNOLOGY AB (SE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070071673-A1 | Trifunctional reagent for conjugation to a biomolecule | UACA, TNFSF11, CD40 | TDP1 3549/4885MEN1 2822/4885ABL1 802/4885 |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | TDP1 593/4885MEN1 3192/4885ABL1 1528/4885 |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | TDP1 593/4885MEN1 3192/4885ABL1 1528/4885 |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | TDP1 593/4885MEN1 3192/4885ABL1 1528/4885 |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | TDP1 593/4885MEN1 3192/4885ABL1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.